1 week Ago By ABMN Staff
Vanguard Group Inc. boosted its stake in shares of Ocular Therapeutix, Inc. ( NASDAQ:OCUL – Free Report ) by 1.
2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 8,483,913 shares of the biopharmaceutical company’s stock after purchasing an additional 99,730 shares during the period. Vanguard Group Inc.
owned 0.05% of Ocular Therapeutix worth $72,453,000 as of its most recent SEC filing. A number of other large investors have also added to or reduced their stakes in the stock.
Teacher Retirement System of Texas increased its holdings in shares of Ocular Therapeutix by 10.0% during the fourth quarter. Teacher Retirement System of Texas now owns 27,777 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 2,526 shares in the last quarter.
China Universal Asset Management Co. Ltd. grew its position in Ocular Therapeutix by 11.
2% during the 4th quarter. China Universal Asset Management Co. Ltd.
now owns 33,336 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 3,347 shares during the last quarter. Sei Investments Co. grew its position in Ocular Therapeutix by 19.
3% during the 4th quarter. Sei Investments Co. now owns 27,742 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 4,496 shares during the last quarter.
Rhumbline Advisers raised its holdings in Ocular Therapeutix by 2.7% in the fourth quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company’s stock worth $1,824,000 after buying an additional 5,682 shares during the last quarter.
Finally, AlphaQuest LLC bought a new position in shares of Ocular Therapeutix in the fourth quarter worth approximately $53,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.
Ocular Therapeutix Price Performance NASDAQ OCUL opened at $6.41 on Friday. The company has a 50-day moving average price of $7.
25 and a 200-day moving average price of $8.59. Ocular Therapeutix, Inc.
has a 52 week low of $4.06 and a 52 week high of $11.78.
The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.
19. The firm has a market capitalization of $1.02 billion, a P/E ratio of -4.
86 and a beta of 1.49. Insider Transactions at Ocular Therapeutix In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction dated Monday, February 24th.
The stock was sold at an average price of $6.87, for a total transaction of $147,533.25.
Following the completion of the sale, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. The trade was a 0.
61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website . Also, insider Donald Notman sold 6,301 shares of the firm’s stock in a transaction dated Friday, January 31st.
The stock was sold at an average price of $7.84, for a total value of $49,399.84.
Following the completion of the transaction, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. This trade represents a 2.
99 % decrease in their position. The disclosure for this sale can be found here . Insiders sold 38,895 shares of company stock worth $283,772 in the last three months.
Corporate insiders own 3.50% of the company’s stock. Analyst Upgrades and Downgrades OCUL has been the subject of several analyst reports.
Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $15.
00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th.
William Blair initiated coverage on Ocular Therapeutix in a research report on Tuesday. They issued an “outperform” rating for the company. Finally, Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th.
They set an “outperform” rating and a $17.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock.
According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.38. View Our Latest Research Report on OCUL About Ocular Therapeutix ( Free Report ) Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States.
The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. Featured Articles Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc.
( NASDAQ:OCUL – Free Report ). Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter .
.
